Effects of Tocilizumab in COVID-19 patients: a cohort study.
Christine A VuKailynn J DeRondeAna D VegaMeshell MaxamGregory HoltYoichiro NatoriJose Gonzales ZamoraVeronica SalazarRenata BoatwrightStephen R MorrisDaniela de Lima CorvinoAnmary Fernandez BetancesLeah ColucciJames KeeganAndy LopezAndrew Hany RezkYvette RodriguezGabriela M MoraruSusanne DobleckiDavid J De La ZerdaLilian M AbboPublished in: BMC infectious diseases (2020)
Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this.
Keyphrases
- rheumatoid arthritis
- sars cov
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- end stage renal disease
- ejection fraction
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- double blind
- prognostic factors
- open label
- peritoneal dialysis
- clinical trial
- disease activity
- emergency department
- placebo controlled
- systemic lupus erythematosus
- phase ii
- study protocol
- case control
- replacement therapy